Skip to main content
$4.50 $0.20 (4.7%)

04:00 PM EDT on 03/27/23

Cti Biopharma Corp (NASDAQ:CTIC)

CAPS Rating: No stars

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Current Price $4.50 Mkt Cap $566.9M
Open $4.32 P/E Ratio 0.00
Prev. Close $4.50 Div. (Yield) $0.00 (0.0%)
Daily Range $4.29 - $4.54 Volume 2,840,481
52-Wk Range $3.32 - $7.80 Avg. Daily Vol. 3,079,406


How do you think NASDAQ:CTIC will perform against the market?

Add Stock to CAPS Watchlist

All Players

234 Outperform
39 Underperform

All-Star Players

13 Outperform
9 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:CTIC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

afrisque61 (< 20)
Submitted February 15, 2015

Once a high-flyer, potentially poised for growth due to new product development.

kanstockman (< 20)
Submitted June 11, 2007

2008 a drug in Phase III stage II should be on the market with a half a billion in sales by the 2nd Q. Right now the stock is being dragged down by the sector componants.

Recent Community Commentary

Read the most recent pitches from players about CTIC.


Member Avatar zzlangerhans (99.73) Submitted: 2/22/2016 11:17:03 AM : Underperform Start Price: $5.07 NASDAQ:CTIC Score: +117.31

I have to admit I got sucked into Cell Therapeutics' transient success with pacritinib and green thumbed them about a year ago, ruining my perfect record on the stock. Fortunately I never followed up that green thumb with a real money bet. As it turned out, pacritinib is going down the toilet along with all of Cell Therapeutics' other programs over the years. A red thumb is still the right bet for this stock no matter how much it looks like they've finally developed a legitimate drug.

This month the company withdrew their NDA for pacritinib thanks to an FDA full clinical hold regarding a detrimental effect of pacritinib on overall survival in both of the two phase III trials. That's a polite way of saying the drug kills people. Not good. Given how bad this looks and Cell Therapeutics' long history of failure, I think we can discard pacritinib from the company's value equation.

What's left? The new lead drug is tosedostat. In December management reported a complete response rate of 49% at an interim analysis of the phase II IST of tosedostat in AML. Tosedostat is also being tested for AML in a "Pick-A-Winner" program developed by the NCRI of the UK. Management is planning discussions regarding registrational trials of tosedostat with regulators in the US and UK later this year. Paclitaxel analogue Opaxio wasn't mentioned in the last earnings PR, although a phase III trial as maintenance therapy in ovarian cancer is supposedly in progress. Pixuvri is showing weak and static revenues, barely over 1M in the last quarter reported. This drug seems to be going nowhere commercially.

Cell Therapeutics has 128M in cash thanks to a series of vulture financings conducted in late 2015. These financings involved the creation of preferred stock equivalent to 90M of common, so there is at least 60M of hidden market cap in addition to the 190M cap based on the outstanding common. There's probably plenty of other preferred stock and options still out there that I haven't kept track of adding to the hidden cap. There's also 52M in long-term debt and a quarterly burn over 20M.

For some reason Cell Therapeutics isn't trading under cash despite the fact that several bios with better pedigrees and prospects are doing exactly that. If we subtract the debt and two quarters of burn from the cash that leaves us with 36M net as of the end of March 2016. Meanwhile, the market cap including preferred stock is over 250M with no positive catalysts apparent on the near term horizon. Cell Therapeutics may be catching a little air for now, but the street has proven to be a harsh mistress for biotech of late. I really don't see this ending well.


Member Avatar 78taxs (43.45) Submitted: 5/28/2015 2:00:01 PM : Outperform Start Price: $18.60 NASDAQ:CTIC Score: -162.78

Cancer. With less rad.


Member Avatar afrisque61 (< 20) Submitted: 2/15/2015 4:33:38 PM : Outperform Start Price: $22.10 NASDAQ:CTIC Score: -168.98

Once a high-flyer, potentially poised for growth due to new product development.


Find the members with the highest scoring picks in CTIC.

Score Leader


ed11b (< 20) Score: +433.84

The Score Leader is the player with the highest score across all their picks in CTIC.

Member Name Member
Call Time
Score Commentary
ed11b < 20 6/26/2009 Underperform 5Y $503.97 -99.11% +334.74% +433.84 0 Comment
AlansMagicStick 46.44 6/29/2009 Underperform 5Y $504.06 -99.11% +332.41% +431.52 0 Comment
f19 < 20 6/4/2009 Underperform 3M $555.00 -99.19% +326.22% +425.41 1 Comment
RoxanneAdams 49.63 6/3/2009 Underperform 5Y $582.00 -99.23% +326.03% +425.26 0 Comment
mcornice 91.44 6/2/2009 Underperform 3M $603.00 -99.25% +324.40% +423.65 0 Comment
thestockstalker < 20 6/1/2009 Underperform NS $462.00 -99.03% +323.59% +422.62 0 Comment
TMFBiologyFool 70.96 8/3/2009 Underperform 1Y $453.00 -99.01% +299.11% +398.11 0 Comment
dcfoolz 73.20 8/28/2009 Underperform 5Y $477.00 -99.06% +282.21% +381.27 0 Comment
TMFNosediveflip 36.18 9/20/2006 Underperform 1Y $2,160.00 -99.79% +218.22% +318.01 0 Comment
cockeagledrvr 67.63 9/29/2006 Underperform 1Y $2,088.00 -99.78% +214.60% +314.38 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CTIC.